Global Bevacizumab Monoclonal Antibody Biosimilar Market Growth 2026-2032

September 2026 | 79 pages | ID: GED896267534EN
LP Information

Abstracts

The global Bevacizumab Monoclonal Antibody Biosimilar market size is predicted to grow from US$ 893 million in 2025 to US$ 292 million in 2032; it is expected to grow at a CAGR of -15.0% from 2026 to 2032.

Avastin Biosimilar is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.

United States market for Bevacizumab Monoclonal Antibody Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Bevacizumab Monoclonal Antibody Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Bevacizumab Monoclonal Antibody Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Bevacizumab Monoclonal Antibody Biosimilar players cover Celltrion, Amneal, Pfizer, Amgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the “Bevacizumab Monoclonal Antibody Biosimilar Industry Forecast” looks at past sales and reviews total world Bevacizumab Monoclonal Antibody Biosimilar sales in 2025, providing a comprehensive analysis by region and market sector of projected Bevacizumab Monoclonal Antibody Biosimilar sales for 2026 through 2032. With Bevacizumab Monoclonal Antibody Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bevacizumab Monoclonal Antibody Biosimilar industry.

This Insight Report provides a comprehensive analysis of the global Bevacizumab Monoclonal Antibody Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bevacizumab Monoclonal Antibody Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bevacizumab Monoclonal Antibody Biosimilar market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bevacizumab Monoclonal Antibody Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bevacizumab Monoclonal Antibody Biosimilar.

This report presents a comprehensive overview, market shares, and growth opportunities of Bevacizumab Monoclonal Antibody Biosimilar market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• 400mg
• 100mg

Segmentation by Application:

• Cancer
• Wet Age-related Macular Degeneration
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Celltrion
• Amneal
• Pfizer
• Amgen

Key Questions Addressed in this Report

• What is the 10-year outlook for the global Bevacizumab Monoclonal Antibody Biosimilar market?
• What factors are driving Bevacizumab Monoclonal Antibody Biosimilar market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Bevacizumab Monoclonal Antibody Biosimilar market opportunities vary by end market size?
• How does Bevacizumab Monoclonal Antibody Biosimilar break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

  1.1 Market Introduction
  1.2 Years Considered
  1.3 Research Objectives
  1.4 Market Research Methodology
  1.5 Research Process and Data Source
  1.6 Economic Indicators
  1.7 Currency Considered
  1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

  2.1 World Market Overview
  2.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Bevacizumab Monoclonal Antibody Biosimilar by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Bevacizumab Monoclonal Antibody Biosimilar by Country/Region, 2021, 2025 & 2032
  2.2 Bevacizumab Monoclonal Antibody Biosimilar Segment by Type
  2.2.1 400mg
  2.2.2 100mg
  2.2.3 Bevacizumab Monoclonal Antibody Biosimilar Sales by Type
  2.2.3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2021-2026)
  2.2.3.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue and Market Share by Type (2021-2026)
  2.2.3.3 Global Bevacizumab Monoclonal Antibody Biosimilar Sale Price by Type (2021-2026)
  2.3 Bevacizumab Monoclonal Antibody Biosimilar Segment by Application
  2.3.1 Cancer
  2.3.2 Wet Age-related Macular Degeneration
  2.3.3 Other
  2.3.4 Bevacizumab Monoclonal Antibody Biosimilar Sales by Application
  2.3.4.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sale Market Share by Application (2021-2026)
  2.3.4.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue and Market Share by Application (2021-2026)
  2.3.4.3 Global Bevacizumab Monoclonal Antibody Biosimilar Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

  3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Breakdown Data by Company
  3.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Annual Sales by Company (2021-2026)
  3.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Company (2021-2026)
  3.2 Global Bevacizumab Monoclonal Antibody Biosimilar Annual Revenue by Company (2021-2026)
  3.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Company (2021-2026)
  3.2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Company (2021-2026)
  3.3 Global Bevacizumab Monoclonal Antibody Biosimilar Sale Price by Company
  3.4 Key Manufacturers Bevacizumab Monoclonal Antibody Biosimilar Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Bevacizumab Monoclonal Antibody Biosimilar Product Location Distribution
  3.4.2 Players Bevacizumab Monoclonal Antibody Biosimilar Products Offered
  3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
  3.6 New Products and Potential Entrants
  3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BEVACIZUMAB MONOCLONAL ANTIBODY BIOSIMILAR BY GEOGRAPHIC REGION

  4.1 World Historic Bevacizumab Monoclonal Antibody Biosimilar Market Size by Geographic Region (2021-2026)
  4.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Annual Revenue by Geographic Region (2021-2026)
  4.2 World Historic Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country/Region (2021-2026)
  4.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Annual Revenue by Country/Region (2021-2026)
  4.3 Americas Bevacizumab Monoclonal Antibody Biosimilar Sales Growth
  4.4 APAC Bevacizumab Monoclonal Antibody Biosimilar Sales Growth
  4.5 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Growth
  4.6 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Growth

5 AMERICAS

  5.1 Americas Bevacizumab Monoclonal Antibody Biosimilar Sales by Country
  5.1.1 Americas Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2021-2026)
  5.1.2 Americas Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2021-2026)
  5.2 Americas Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026)
  5.3 Americas Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2021-2026)
  5.4 United States
  5.5 Canada
  5.6 Mexico
  5.7 Brazil

6 APAC

  6.1 APAC Bevacizumab Monoclonal Antibody Biosimilar Sales by Region
  6.1.1 APAC Bevacizumab Monoclonal Antibody Biosimilar Sales by Region (2021-2026)
  6.1.2 APAC Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region (2021-2026)
  6.2 APAC Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026)
  6.3 APAC Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2021-2026)
  6.4 China
  6.5 Japan
  6.6 South Korea
  6.7 Southeast Asia
  6.8 India
  6.9 Australia
  6.10 China Taiwan

7 EUROPE

  7.1 Europe Bevacizumab Monoclonal Antibody Biosimilar by Country
  7.1.1 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2021-2026)
  7.1.2 Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2021-2026)
  7.2 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026)
  7.3 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2021-2026)
  7.4 Germany
  7.5 France
  7.6 UK
  7.7 Italy
  7.8 Russia

8 MIDDLE EAST & AFRICA

  8.1 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar by Country
  8.1.1 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2021-2026)
  8.2 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026)
  8.3 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2021-2026)
  8.4 Egypt
  8.5 South Africa
  8.6 Israel
  8.7 Turkey
  8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

  9.1 Market Drivers & Growth Opportunities
  9.2 Market Challenges & Risks
  9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

  10.1 Raw Material and Suppliers
  10.2 Manufacturing Cost Structure Analysis of Bevacizumab Monoclonal Antibody Biosimilar
  10.3 Manufacturing Process Analysis of Bevacizumab Monoclonal Antibody Biosimilar
  10.4 Industry Chain Structure of Bevacizumab Monoclonal Antibody Biosimilar

11 MARKETING, DISTRIBUTORS AND CUSTOMER

  11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
  11.2 Bevacizumab Monoclonal Antibody Biosimilar Distributors
  11.3 Bevacizumab Monoclonal Antibody Biosimilar Customer

12 WORLD FORECAST REVIEW FOR BEVACIZUMAB MONOCLONAL ANTIBODY BIOSIMILAR BY GEOGRAPHIC REGION

  12.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size Forecast by Region
  12.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Forecast by Region (2027-2032)
  12.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Annual Revenue Forecast by Region (2027-2032)
  12.2 Americas Forecast by Country (2027-2032)
  12.3 APAC Forecast by Region (2027-2032)
  12.4 Europe Forecast by Country (2027-2032)
  12.5 Middle East & Africa Forecast by Country (2027-2032)
  12.6 Global Bevacizumab Monoclonal Antibody Biosimilar Forecast by Type (2027-2032)
  12.7 Global Bevacizumab Monoclonal Antibody Biosimilar Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

  13.1 Celltrion
  13.1.1 Celltrion Company Information
  13.1.2 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Product Portfolios and Specifications
  13.1.3 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 Celltrion Main Business Overview
  13.1.5 Celltrion Latest Developments
  13.2 Amneal
  13.2.1 Amneal Company Information
  13.2.2 Amneal Bevacizumab Monoclonal Antibody Biosimilar Product Portfolios and Specifications
  13.2.3 Amneal Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 Amneal Main Business Overview
  13.2.5 Amneal Latest Developments
  13.3 Pfizer
  13.3.1 Pfizer Company Information
  13.3.2 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Product Portfolios and Specifications
  13.3.3 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
  13.3.4 Pfizer Main Business Overview
  13.3.5 Pfizer Latest Developments
  13.4 Amgen
  13.4.1 Amgen Company Information
  13.4.2 Amgen Bevacizumab Monoclonal Antibody Biosimilar Product Portfolios and Specifications
  13.4.3 Amgen Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
  13.4.4 Amgen Main Business Overview
  13.4.5 Amgen Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Bevacizumab Monoclonal Antibody Biosimilar Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Bevacizumab Monoclonal Antibody Biosimilar Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 400mg
Table 4. Major Players of 100mg
Table 5. Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026) & (K Units)
Table 6. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2021-2026)
Table 7. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Type (2021-2026) & ($ million)
Table 8. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2021-2026)
Table 9. Global Bevacizumab Monoclonal Antibody Biosimilar Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Bevacizumab Monoclonal Antibody Biosimilar Sale by Application (2021-2026) & (K Units)
Table 11. Global Bevacizumab Monoclonal Antibody Biosimilar Sale Market Share by Application (2021-2026)
Table 12. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Application (2021-2026) & ($ million)
Table 13. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2021-2026)
Table 14. Global Bevacizumab Monoclonal Antibody Biosimilar Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Company (2021-2026) & (K Units)
Table 16. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Company (2021-2026)
Table 17. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Company (2021-2026)
Table 19. Global Bevacizumab Monoclonal Antibody Biosimilar Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Bevacizumab Monoclonal Antibody Biosimilar Producing Area Distribution and Sales Area
Table 21. Players Bevacizumab Monoclonal Antibody Biosimilar Products Offered
Table 22. Bevacizumab Monoclonal Antibody Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share Geographic Region (2021-2026)
Table 27. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country/Region (2021-2026)
Table 31. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2021-2026) & (K Units)
Table 34. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2021-2026)
Table 35. Americas Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026) & (K Units)
Table 37. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2021-2026) & (K Units)
Table 38. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales by Region (2021-2026) & (K Units)
Table 39. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2021-2026)
Table 40. APAC Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026) & (K Units)
Table 42. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2021-2026) & (K Units)
Table 43. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2021-2026) & (K Units)
Table 44. Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026) & (K Units)
Table 46. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Bevacizumab Monoclonal Antibody Biosimilar
Table 52. Key Market Challenges & Risks of Bevacizumab Monoclonal Antibody Biosimilar
Table 53. Key Industry Trends of Bevacizumab Monoclonal Antibody Biosimilar
Table 54. Bevacizumab Monoclonal Antibody Biosimilar Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Bevacizumab Monoclonal Antibody Biosimilar Distributors List
Table 57. Bevacizumab Monoclonal Antibody Biosimilar Customer List
Table 58. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Bevacizumab Monoclonal Antibody Biosimilar Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Bevacizumab Monoclonal Antibody Biosimilar Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Celltrion Basic Information, Bevacizumab Monoclonal Antibody Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 73. Celltrion Bevacizumab Monoclonal Antibody Biosimilar Product Portfolios and Specifications
Table 74. Celltrion Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Celltrion Main Business
Table 76. Celltrion Latest Developments
Table 77. Amneal Basic Information, Bevacizumab Monoclonal Antibody Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 78. Amneal Bevacizumab Monoclonal Antibody Biosimilar Product Portfolios and Specifications
Table 79. Amneal Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Amneal Main Business
Table 81. Amneal Latest Developments
Table 82. Pfizer Basic Information, Bevacizumab Monoclonal Antibody Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer Bevacizumab Monoclonal Antibody Biosimilar Product Portfolios and Specifications
Table 84. Pfizer Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. Amgen Basic Information, Bevacizumab Monoclonal Antibody Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 88. Amgen Bevacizumab Monoclonal Antibody Biosimilar Product Portfolios and Specifications
Table 89. Amgen Bevacizumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Amgen Main Business
Table 91. Amgen Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Bevacizumab Monoclonal Antibody Biosimilar
Figure 2. Bevacizumab Monoclonal Antibody Biosimilar Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Bevacizumab Monoclonal Antibody Biosimilar Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country/Region (2025)
Figure 10. Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 400mg
Figure 12. Product Picture of 100mg
Figure 13. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type in 2026
Figure 14. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2021-2026)
Figure 15. Bevacizumab Monoclonal Antibody Biosimilar Consumed in Cancer
Figure 16. Global Bevacizumab Monoclonal Antibody Biosimilar Market: Cancer (2021-2026) & (K Units)
Figure 17. Bevacizumab Monoclonal Antibody Biosimilar Consumed in Wet Age-related Macular Degeneration
Figure 18. Global Bevacizumab Monoclonal Antibody Biosimilar Market: Wet Age-related Macular Degeneration (2021-2026) & (K Units)
Figure 19. Bevacizumab Monoclonal Antibody Biosimilar Consumed in Other
Figure 20. Global Bevacizumab Monoclonal Antibody Biosimilar Market: Other (2021-2026) & (K Units)
Figure 21. Global Bevacizumab Monoclonal Antibody Biosimilar Sale Market Share by Application (2025)
Figure 22. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Application in 2026
Figure 23. Bevacizumab Monoclonal Antibody Biosimilar Sales by Company in 2026 (K Units)
Figure 24. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Company in 2026
Figure 25. Bevacizumab Monoclonal Antibody Biosimilar Revenue by Company in 2026 ($ millions)
Figure 26. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Company in 2026
Figure 27. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales 2021-2026 (K Units)
Figure 30. Americas Bevacizumab Monoclonal Antibody Biosimilar Revenue 2021-2026 ($ millions)
Figure 31. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales 2021-2026 (K Units)
Figure 32. APAC Bevacizumab Monoclonal Antibody Biosimilar Revenue 2021-2026 ($ millions)
Figure 33. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales 2021-2026 (K Units)
Figure 34. Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue 2021-2026 ($ millions)
Figure 37. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country in 2026
Figure 38. Americas Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2021-2026)
Figure 39. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2021-2026)
Figure 40. Americas Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2021-2026)
Figure 41. United States Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Region in 2026
Figure 46. APAC Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2021-2026)
Figure 47. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2021-2026)
Figure 48. APAC Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2021-2026)
Figure 49. China Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 53. India Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country in 2026
Figure 57. Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Country (2021-2026)
Figure 58. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2021-2026)
Figure 59. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2021-2026)
Figure 60. Germany Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 61. France Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2021-2026)
Figure 68. Egypt Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Bevacizumab Monoclonal Antibody Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Bevacizumab Monoclonal Antibody Biosimilar in 2026
Figure 74. Manufacturing Process Analysis of Bevacizumab Monoclonal Antibody Biosimilar
Figure 75. Industry Chain Structure of Bevacizumab Monoclonal Antibody Biosimilar
Figure 76. Channels of Distribution
Figure 77. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Forecast by Region (2027-2032)
Figure 78. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share Forecast by Application (2027-2032)